Estrella Immunopharma (ESLA) News Today $1.03 +0.08 (+7.81%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ESLA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Estrella Immunopharma (NASDAQ:ESLA) Trading Up 1% - Should You Buy?August 19, 2025 | americanbankingnews.comIs Estrella Immunopharma (NASDAQ:ESLA) In A Good Position To Deliver On Growth Plans?August 14, 2025 | finance.yahoo.comEstrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s LymphomaJune 5, 2025 | finance.yahoo.comEstrella Immunopharma to sell 2.333M shares at $1.50 in private placementJune 4, 2025 | msn.comEstrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity FinancingJune 4, 2025 | finance.yahoo.comESLA Estrella Immunopharma, Inc.May 30, 2025 | seekingalpha.comEstrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II TrialMay 29, 2025 | msn.comEstrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s LymphomasMay 29, 2025 | finance.yahoo.comEstrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's LymphomasMay 29, 2025 | businesswire.comEstrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital PartnersMarch 5, 2025 | finance.yahoo.comEstrella Immunopharma completes first dose cohort in STARLIGHT trialFebruary 21, 2025 | markets.businessinsider.comEstrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose CohortFebruary 21, 2025 | businesswire.comEstrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral CapitalFebruary 19, 2025 | businesswire.comD. Boral Capital Initiates Coverage of Estrella Immunopharma (ESLA) with Buy RecommendationFebruary 19, 2025 | msn.comSpotlight On US Penny Stocks: Estrella Immunopharma And Two Others To ConsiderNovember 19, 2024 | uk.finance.yahoo.comEstrella Immunopharma (NASDAQ:ESLA) Stock, Short Interest ReportOctober 11, 2024 | benzinga.comEstrella Immunopharma (NASDAQ:ESLA) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comEstrella Immunopharma Shares Rise on Lymphoma Patient's Treatment ResponseSeptember 28, 2024 | marketwatch.comEstrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cellsSeptember 27, 2024 | finance.yahoo.comEstrella Immunopharma, Inc. (ESLAW)August 24, 2024 | uk.finance.yahoo.comEstrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest UpdateJuly 30, 2024 | marketbeat.comESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024May 20, 2024 | investorplace.comEntheon Biomedical Corp. (ENTBD)March 7, 2024 | finance.yahoo.comEstrella Immunopharma Approves $1 Million Stock Buyback ProgramJanuary 31, 2024 | msn.comWhy DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving PremarketJanuary 17, 2024 | msn.comEstrella Immunopharma Inc (ESLA)November 23, 2023 | uk.investing.comEstrella Immunopharma, Inc. (ESLA)November 3, 2023 | finance.yahoo.comEstrella Immunopharma Inc ESLANovember 1, 2023 | morningstar.comMWe Think Estrella Immunopharma (NASDAQ:ESLA) Can Afford To Drive Business GrowthOctober 20, 2023 | finance.yahoo.comEstrella Immunopharma (Nasdaq:ESLA) HeadlineTrading was temporarily halted for "ESLA" at 09:10 AM with a stated reason of "LULD pause."...October 2, 2023 | marketbeat.com Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ESLA Media Mentions By Week ESLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESLA News Sentiment▼1.871.03▲Average Medical News Sentiment ESLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESLA Articles This Week▼10▲ESLA Articles Average Week Get the Latest News and Ratings for ESLA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Estrella Immunopharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Citius Oncology News Today Fate Therapeutics News Today TuHURA Biosciences News Today Compugen News Today Alpha Cognition News Today Genelux News Today Inhibikase Therapeutics News Today Scilex News Today Coherus Oncology News Today Cognition Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ESLA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.